Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated January 13, 2025, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The filing details share acquisitions executed on January 9 and January 10, 2025, on the London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain corporate financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on individual share transactions.
| Instrument | Transaction Date | Price | Total Volume (Shares/ADSs) | Exchange |
|---|---|---|---|---|
| Ordinary Shares (GBP) | 2025-01-09 | £13.5574 | 23,328.302 | London Stock Exchange |
| American Depositary Shares (USD) | 2025-01-10 | $33.3533 | 323 | New York Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position or operations. The reported changes are limited to the increase in shareholdings of specific executives and directors resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of all reported transactions is the acquisition of shares following the re-investment of dividends paid to shareholders on January 9, 2025.
Investor Verification Points
- Transaction Nature: Verify that all reported acquisitions were automatic dividend reinvestments and not open-market purchases or sales.
- Executive Participation: Confirm the list of participating PDMRs includes the CEO (Emma Walmsley), Chief Commercial Officer (Luke Miels), and various Non-Executive Directors.
- Share Price Consistency: Note the uniform transaction price of £13.5574 for Ordinary Shares and $33.3533 for ADSs across all participants on their respective dates.
- Reporting Scope: Acknowledge that this document does not provide quarterly or annual financial performance data.